NEW YORK (AP) — French drugmaker NicOx SA said Tuesday it is seeking approval to market its osteoarthritis drug candidate naproxcinod in the European Union. NicOx filed for approval from the European Medicines Agency. The company asked for U.S. marketing approval in September and said it expects the Food and Drug Administration to complete its review by July 24, 2010. The company’s U.S. business is headquartered in Warren, N.J.
